News + Filings Transactions Holdings
All 13F 13D/G Other
|
New Enterprise Associates 15, L.P.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/28/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
08/21/2023 |
SC 13D/A
| New Enterprise Associates 15, L.P. reports a 50.7% stake in Bright Health Group, Inc. |
06/09/2023 |
SC 13D/A
| New Enterprise Associates 15, L.P. has filed a Schedule 13D for IonQ, Inc. |
01/24/2023 |
SC 13D/A
| New Enterprise Associates 15, L.P. reports a 10.8% stake in Arcellx, Inc. |
12/12/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
06/06/2022 |
SC 13D/A
| New Enterprise Associates 15, L.P. reports a 13.3% stake in IonQ, Inc. |
05/05/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
05/05/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
02/08/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
01/26/2022 |
SC 13D/A
| New Enterprise Associates 15, L.P. reports a 39% stake in Bright Health Group, Inc. |
12/29/2021 |
SC 13D/A
| New Enterprise Associates 15, L.P. reports a 34.7% stake in Bright Health Group, Inc. |
10/07/2021 |
SC 13D/A
| New Enterprise Associates 15, L.P. reports a 5.5% stake in Desktop Metal, Inc. |
06/22/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
06/03/2021 |
SC 13D/A
| New Enterprise Associates 15, L.P. reports a 11.7% stake in Eargo, Inc. |
04/13/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
06/12/2019 |
SC 13D/A
| New Enterprise Associates 15, L.P. has filed a Schedule 13D for Nightstar Therapeutics plc |
03/13/2019 |
SC 13D/A
| New Enterprise Associates 15, L.P. reports a 19.9% stake in Nightstar Therapeutics plc |
10/09/2018 |
SC 13D/A
| New Enterprise Associates 15, L.P. reports a 20.3% stake in Nightstar Therapeutics plc |
|
|